Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects

Jesse Hall,1 Michael Gillen,2 Sha Liu,1 Jeffrey N Miner,1 Shakti Valdez,1 Zancong Shen,1 Caroline Lee1 1Ardea Biosciences, Inc., San Diego, CA, USA; 2AstraZeneca, Gaithersburg, MD, USA Purpose: Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for treatme...

Full description

Bibliographic Details
Main Authors: Hall J, Gillen M, Liu S, Miner JN, Valdez S, Shen Z, Lee C
Format: Article
Language:English
Published: Dove Medical Press 2018-06-01
Series:Drug Design, Development and Therapy
Subjects:
Pharmacokinetics
pharmacodynamics
selective uric acid reabsorption inhibitor
serum urate
urinary uric acid
Online Access:https://www.dovepress.com/ppharmacokinetics-pharmacodynamics-and-tolerability-of-verinurad--peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/ppharmacokinetics-pharmacodynamics-and-tolerability-of-verinurad--peer-reviewed-article-DDDT

Similar Items